Skip to main content

Dr. Jessica A. Hellyer

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
12
In the NPI registry since
2014
Medicare patients seen, 2024
330

Licensed in Washington since 2021, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2014Medical school: University of Colorado School of Medicine, Denver
  • 2014Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    WA license MD61214270 (first issued 2021; expired) · CO license DR.0074593 (first issued 2025; active)
  • Internal Medicine Physician
    PA license MD470698

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
330
Services billed
111,525
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, pembrolizumab, 1 mg13,60017
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml9,46062
Injection, aprepitant, 1 mg9,36033
Injection, paclitaxel, 1 mg3,80513
Injection, lanreotide, 1 mg3,24011
Injection, dexamethasone sodium phosphate, 1 mg2,26866
Injection, granisetron hydrochloride, 100 mcg91132
Injection, palonosetron hcl, 25 mcg89038
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count51997
Injection of additional new drug or substance into vein48574

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 24 companies reported 41 payments worth $2,195 in total to this clinician.

By type
Consulting Fee$1,160
Food and Beverage$1,035

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
May 22, 2025Boehringer Ingelheim Pharmaceuticals, Inc.
May 22, 2025
Consulting Fee$1,160

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Pennsylvania →

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $258,955 in research payments for these studies, mostly to the institutions running them.

  • A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy f…
    AstraZeneca Pharmaceuticals LP
  • A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose …
    AstraZeneca UK Limited
  • A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
    Beone Medicines Ltd. · Completed · NCT05909904
  • This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab MEDI4736 and domvanalimab AB154 compared with durvalumab plus placebo…
    AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Philadelphia

Sources

NPI registry (CMS NPPES, November 2026; record last updated May 14, 2025), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1235557398. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.